Iconic Labs Regulatory News (ICON)

8 August 2023

Iconic Labs PLC

("Iconic" or the "Company")

Publication of Prospectus and Issue of Equity

Iconic Labs PLC (LSE: ICON) today announces the publication of its Prospectus (the "Prospectus") to shareholders. The Prospectus gives Iconic the ability to issue Ordinary Shares as it finalises its overall restructuring obligations. These shares will be available to meet obligations towards:

· the European High Growth Opportunities Securitization Fund ("EHGOSF") and Linton Capital LLP under the 23 August 2022 Settlement Deed;

· the unsecured creditors under the 22 September 2022 Company Voluntary Agreement;

· EHGOSF under the 28 September 2022 £3 million financing facility; and

· management for outstanding fees. 

The Prospectus has been approved by the Financial Conduct Authority and is available to view on the Company's website: https://www.iconiclabs.co.uk/documents/ and at the National Storage Mechanism: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Brad Taylor, Chief Executive Officer of Iconic Labs, commented:

"We are pleased to announce the publication of the Company's Prospectus as we near the completion of this complex two-year restructuring process. Critically, the Prospectus also enables us to access the next tranches of financing with EHGOSF so that Iconic can finally shift its focus from the mechanics of restructuring to generating shareholder value.

"With a highly experienced team based in the US, UK and Europe, we are well-positioned to explore strategic acquisition options, which may include the possibility of an RTO, and the development of our current media business including owned brands such as GSN.

"The Board looks forward to updating the market in due course."

- Ends -

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR") and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

For more information, please contact: